Sigyn Therapeutics (Sigyn Therapeutics) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sigyn Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Sigyn Therapeutics ROCE % Historical Data

The historical data trend for Sigyn Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics ROCE % Chart

Sigyn Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-6,784.00

Sigyn Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Sigyn Therapeutics ROCE % Calculation

Sigyn Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.102	/	( ( (0.333 - 2.049)	+	(0.322 - 3.608) )	/ 2 )
	=	-2.102	/	( (-1.716	+	-3.286)	/ 2 )
	=	-2.102	/	-2.501
	=	84.05 %

Sigyn Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2.52	/	( ( (0.322 - 3.608)	+	(0.323 - 4.235) )	/ 2 )
	=	-2.52	/	( ( -3.286	+	-3.912 )	/ 2 )
	=	-2.52	/	-3.599
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Sigyn Therapeutics (OTCPK:SIGY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sigyn Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics (Sigyn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212